72 completed, 5 terminated, 5 unknown, 3 recruiting. 29 Phase 3, 21 Phase 2, 14 Not applicable, 11 Phase 4, 8 Phase 1.
Follow Sevelamer: new trials by email Literature Review of Sevelamer trials Research Report on Sevelamer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia JMKX003002 will be administered orally, Sevelamer carbonate - Hyperphosphatemia | Phase 2 | Recruiting | Jemincare | 50 | 2024-12-30 | 2025-02-03 |
| Calcium-Phosphorus Regulation Therapy on Heart Valve Disease Sevelamer, Calcium carbonate - Degenerative Heart Valve Disease, Heart Valve Calcification | Phase 4 | Recruiting | China National Center for Cardiovascular Diseases | 196 | 2024-03-01 | 2024-10-28 |
| AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia AP301, Sevelamer carbonate (Renvela®), AP301 Low Dose - ESRD (End Stage Renal Disease), Chronic Kidney Disease(CKD) | Phase 3 | Completed | Alebund Pharmaceuticals | 474 | 2023-06-12 | 2025-11-17 |
| A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients AP-306, Sevelamer Carbonate - Chronic Kidney Diseases, Hyperphosphatemia | Phase 2 | Completed | Alebund Pharmaceuticals | 55 | 2023-02-20 | 2024-01-10 |
| Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders Tecovirimat, sevelamer carbonate oral tablet, sucroferric oxyhydroxide chewable tablet - Smallpox | Phase 4 | Completed | SIGA Technologies | 44 | 2022-06-08 | 2026-09-11 |
| A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis Patients VS-505, Sevelamer Carbonate - Hyperphosphatemia | Phase 2 | Completed | Shanghai Alebund Pharmaceuticals Limited | 158 | 2020-10-13 | 2022-10-18 |
| Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of Vadadustat Vadadustat, Sevelamer carbonate, Calcium acetate - Healthy Volunteers | Phase 1 | Completed | Akebia Therapeutics | 54 | 2020-06-15 | 2020-10-08 |
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: - Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension | Recruiting | Duke University | 5000 | 2020-03-05 | 2026-08-21 | |
| Assessing Bone Calcium Content in Children With Kidney Disease Treated With Two Different Medicines calcium carbonate, sevelamer carbonate - Chronic Kidney Diseases | Not applicable | Unknown | University College, London | 21 | 2020-01-07 | 2021-08-12 |
| Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis Ferric Citrate, Sevelamer Carbonate - Hyperphosphatemia, End Stage Renal Disease | Phase 3 | Completed | Panion & BF Biotech Inc. | 240 | 2019-06-19 | 2021-03-10 |
| A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP Tenapanor, Sevelamer Carbonate - Hyperphosphatemia, End Stage Renal Disease | Phase 4 | Completed | Ardelyx | 172 | 2019-06-15 | 2023-03-29 |
| Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis Ferric citrate tablet, Sevelamer carbonate tablet - Hyperphosphatemia, End Stage Renal Disease | Phase 3 | Completed | Sinomune Pharmaceutical Co., Ltd | 239 | 2019-05-24 | 2024-04-17 |
| Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy Tenapanor, Placebo, Phosphate Binder Agents - Hyperphosphatemia | Phase 2 / Phase 3 | Completed | Ardelyx | 236 | 2019-02-28 | 2023-03-06 |
| GLP-1-mediated Gluco-metabolic Effects of Bile Acid Sequestration Sevelamer, Placebo - Type 2 Diabetes Mellitus | Not applicable | Completed | Steno Diabetes Center Copenhagen | 17 | 2018-09-01 | 2021-10-13 |
| The Effect of Sevelamer Carbonate on Serum Trimethylamine-n-Oxide (TMAO) Level in Patients With Chronic Kidney Disease (CKD) Stage 3b-4 Sevelamer Carbonate - CKD Stage 3b, CKD Stage 4 | Phase 3 | Unknown | Fan Fan Hou | 80 | 2018-09-01 | 2018-08-07 |
| PA21 Safety and Efficacy in Adult Chinese Subjects PA21, sevelamer carbonate - Chronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia | Phase 3 | Completed | Vifor Fresenius Medical Care Renal Pharma | 286 | 2018-08-31 | 2021-06-02 |
| Different Effects of Non-calcium Phosphate Binders on Serum Calcium Sevelamer Hydrochloride, Lanthanum Carbonate - Chronic Kidney Disease | Phase 4 | Completed | Medical University of Lodz | 34 | 2018-03-01 | 2021-07-27 |
| A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis Tenapanor, Placebo, Sevelamer Carbonate - Hyperphosphatemia | Phase 3 | Completed | Ardelyx | 1559 | 2018-01-08 | 2023-06-29 |
| DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis DS-2330b PIB, Placebo, Sevelamer - Hyperphosphatemia | Phase 1 | Completed | Daiichi Sankyo | 40 | 2017-08-17 | 2019-03-25 |
| Hyperphosphatemia in Children With Chronic Kidney Disease Calcium acetate and sevelamer hydrochloride - Hyperphosphatemia | Phase 3 | Unknown | Assiut University | 40 | 2017-08-01 | 2017-06-28 |
Showing 20 of 87. Sign in to see all of them.
Hyperphosphatemia (37) · Renal Insufficiency, Chronic (37) · Kidney Failure, Chronic (14) · Renal Insufficiency (6) · Hyperparathyroidism, Secondary (5) · Arrhythmias, Cardiac (3) · Diabetes Mellitus, Type 2 (3) · Hypertension (3) · Insulin Resistance (3) · Vascular Calcification (3) · Cardiovascular Diseases (2) · Chronic Kidney Disease-Mineral and Bone Disorder (2) · Diabetic Nephropathies (2) · Heart Failure (2) · Hemophilia A (2)
Genzyme, a Sanofi Company (13) · Ardelyx (4) · Shire (3) · Vifor Pharma (3) · Alebund Pharmaceuticals (2) · Astellas Pharma Inc (2) · Centre Hospitalier Universitaire, Amiens (2) · Gulhane School of Medicine (2) · Ineos Healthcare Limited (2) · Novartis Pharmaceuticals (2) · Tanabe Pharma Corporation (2) · The University of Texas Health Science Center at San Antonio (2) · University Hospital, Gentofte, Copenhagen (2) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (1) · Akebia Therapeutics (1)
United States (38) · United Kingdom (14) · China (11) · Germany (11) · France (10) · Italy (10) · Poland (7) · Austria (6) · Czechia (6) · Denmark (6) · Belgium (5) · Puerto Rico (5) · Russia (5) · South Africa (5) · Spain (5)
David P Rosenbaum, PhD (3) · Juergen Floege, MD (2) · Nicolas Musi, MD. (2) · Adrian Covic, Prof (1) · Anders Alvestrand, MD PhD (1) · Angela YM Wang, MD, PhD (1) · Biagio R Di Iorio, MD, PhD (1) · Charles J Ferro, BSc (Hons), MBChB, FRCP, MD (1) · Chi Hornik (1)
PMID 40576086, PMID 38323855, PMID 21854503, PMID 29656600, PMID 37853560, PMID 16880182, PMID 16940716, PMID 17276178, PMID 17728707, PMID 17805238, PMID 18057307, PMID 18089452, PMID 18199805, PMID 18235525, PMID 18295050, PMID 18295060, PMID 18310864, PMID 18336094, PMID 18400812, PMID 18414441, PMID 18423809, PMID 18451682, PMID 18573137, PMID 18765433, PMID 19414839, PMID 19967647, PMID 20042256, PMID 20048204, PMID 20921291, PMID 21288351, PMID 21354682, PMID 22137672, PMID 22461535, PMID 22742720, PMID 24197066, PMID 24614374, PMID 24864123, PMID 24949994, PMID 24975892, PMID 25027030, PMID 25685872, PMID 26039810, PMID 26239948, PMID 26926644, PMID 26951967, PMID 27007989, PMID 27357090, PMID 27522443, PMID 28137820, PMID 28290120
2008 (2), U01AI068636 (1)